AFMD – Affimed N.V.
Affimed N.V.AFMD
$0.6001Name : Affimed N.V.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $9,837,019.00
EPSttm : -4.91
Affimed N.V.
$0.6001
5.05%$0.0319Float Short %
4.63
Margin Of Safety %
Put/Call OI Ratio
0.07
EPS Next Q Diff
0.48
EPS Last/This Y
3.36
EPS This/Next Y
1.18
Price
0.63
Target Price
11.48
Analyst Recom
1
Performance Q
-46.89
Relative Volume
1.57
Beta
2.14
Ticker: AFMD
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | AFMD | 1.02 | 0.08 | 0.00 | 711 |
| 2025-03-06 | AFMD | 0.98 | 0.08 | 0.00 | 711 |
| 2025-03-07 | AFMD | 0.973 | 0.08 | 0.00 | 726 |
| 2025-03-10 | AFMD | 0.93 | 0.08 | 0.00 | 726 |
| 2025-03-11 | AFMD | 0.897 | 0.08 | 0.00 | 737 |
| 2025-03-12 | AFMD | 0.88 | 0.07 | 0.00 | 803 |
| 2025-03-13 | AFMD | 0.8628 | 0.07 | 0.00 | 803 |
| 2025-03-14 | AFMD | 0.87 | 0.07 | 0.00 | 803 |
| 2025-03-17 | AFMD | 0.8999 | 0.07 | 0.00 | 803 |
| 2025-03-18 | AFMD | 0.89 | 0.07 | 0.00 | 803 |
| 2025-03-19 | AFMD | 0.9009 | 0.07 | 0.00 | 803 |
| 2025-03-20 | AFMD | 0.8805 | N/A | N/A | 0 |
| 2025-03-21 | AFMD | 0.9164 | 0.07 | 0.00 | 818 |
| 2025-03-24 | AFMD | 0.8707 | 0.07 | 0.00 | 810 |
| 2025-03-25 | AFMD | 0.871 | 0.07 | 0.00 | 810 |
| 2025-03-26 | AFMD | 0.8121 | 0.07 | 0.00 | 810 |
| 2025-03-27 | AFMD | 0.805 | 0.07 | 0.00 | 810 |
| 2025-03-28 | AFMD | 0.7754 | 0.07 | 0.00 | 809 |
| 2025-03-31 | AFMD | 0.73 | 0.07 | 0.00 | 825 |
| 2025-04-01 | AFMD | 0.7098 | 0.07 | 0.00 | 827 |
| 2025-04-02 | AFMD | 0.7066 | 0.07 | 0.00 | 827 |
| 2025-04-03 | AFMD | 0.6306 | 0.07 | 0.00 | 827 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | AFMD | 0.96 | 86.8 | - | -3.96 |
| 2025-03-06 | AFMD | 0.97 | 86.8 | - | -3.96 |
| 2025-03-07 | AFMD | 0.99 | 86.8 | - | -3.96 |
| 2025-03-10 | AFMD | 0.92 | 86.8 | - | -3.96 |
| 2025-03-11 | AFMD | 0.91 | 86.8 | - | -3.96 |
| 2025-03-12 | AFMD | 0.90 | 86.8 | - | -3.96 |
| 2025-03-13 | AFMD | 0.87 | 86.8 | - | -3.96 |
| 2025-03-14 | AFMD | 0.88 | 86.8 | - | -3.96 |
| 2025-03-17 | AFMD | 0.90 | 86.8 | - | -3.96 |
| 2025-03-18 | AFMD | 0.89 | 86.8 | - | -3.96 |
| 2025-03-19 | AFMD | 0.89 | 86.8 | - | -3.96 |
| 2025-03-20 | AFMD | 0.90 | 86.8 | - | -3.96 |
| 2025-03-21 | AFMD | 0.88 | 86.8 | - | -3.96 |
| 2025-03-24 | AFMD | 0.87 | 86.8 | - | -3.96 |
| 2025-03-25 | AFMD | 0.88 | 86.8 | - | -3.96 |
| 2025-03-26 | AFMD | 0.83 | 86.8 | - | -3.96 |
| 2025-03-27 | AFMD | 0.80 | 86.8 | - | -3.96 |
| 2025-03-28 | AFMD | 0.78 | 86.8 | - | -3.96 |
| 2025-03-31 | AFMD | 0.73 | 86.8 | - | -3.96 |
| 2025-04-01 | AFMD | 0.71 | 86.8 | - | -3.96 |
| 2025-04-02 | AFMD | 0.71 | 86.8 | - | -3.96 |
| 2025-04-03 | AFMD | 0.63 | 86.8 | - | -3.96 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | AFMD | 0.00 | -5.43 | 5.39 |
| 2025-03-06 | AFMD | 0.00 | -5.43 | 5.39 |
| 2025-03-07 | AFMD | 0.00 | -5.43 | 5.39 |
| 2025-03-10 | AFMD | 0.00 | -5.43 | 5.39 |
| 2025-03-11 | AFMD | 0.00 | -5.43 | 5.39 |
| 2025-03-12 | AFMD | 0.00 | -5.43 | 5.44 |
| 2025-03-13 | AFMD | 0.00 | -5.43 | 5.44 |
| 2025-03-14 | AFMD | 0.00 | -5.43 | 5.44 |
| 2025-03-17 | AFMD | 0.00 | -5.25 | 5.44 |
| 2025-03-18 | AFMD | 0.00 | -5.25 | 5.44 |
| 2025-03-19 | AFMD | 0.00 | -5.25 | 5.44 |
| 2025-03-20 | AFMD | 0.00 | -5.25 | 5.44 |
| 2025-03-21 | AFMD | 0.00 | -5.25 | 5.44 |
| 2025-03-24 | AFMD | 0.00 | -5.86 | 5.44 |
| 2025-03-25 | AFMD | 0.00 | -5.86 | 5.44 |
| 2025-03-26 | AFMD | 0.00 | -5.86 | 4.63 |
| 2025-03-27 | AFMD | 0.00 | -5.86 | 4.63 |
| 2025-03-28 | AFMD | 0.00 | -5.86 | 4.63 |
| 2025-03-31 | AFMD | 0.00 | -5.86 | 4.63 |
| 2025-04-01 | AFMD | 0.00 | -5.86 | 4.63 |
| 2025-04-02 | AFMD | 0.00 | -5.86 | 4.63 |
| 2025-04-03 | AFMD | 0.00 | -5.86 | 4.63 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.03
Avg. EPS Est. Current Quarter
-0.8
Avg. EPS Est. Next Quarter
-0.55
Insider Transactions
Institutional Transactions
-5.86
Beta
2.14
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
1
Fair Value
Quality Score
15
Growth Score
35
Sentiment Score
18
Actual DrawDown %
99.5
Max Drawdown 5-Year %
-99.4
Target Price
11.48
P/E
Forward P/E
PEG
P/S
10.13
P/B
0.54
P/Free Cash Flow
EPS
-3.64
Average EPS Est. Cur. Y
-3.96
EPS Next Y. (Est.)
-2.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-7992.6
Relative Volume
1.57
Return on Equity vs Sector %
-426.7
Return on Equity vs Industry %
-413.9
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.09
EBIT Estimation
Affimed N.V.Sector: Healthcare
Industry: Biotechnology
Employees: 76
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.
stock quote shares AFMD – Affimed N.V. Stock Price stock today
news today AFMD – Affimed N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch AFMD – Affimed N.V. yahoo finance google finance
stock history AFMD – Affimed N.V. invest stock market
stock prices AFMD premarket after hours
ticker AFMD fair value insiders trading